Showing 2071-2080 of 3832 results for "".
- PDO Max Launches Molded Levo Max Threadshttps://modernaesthetics.com/news/pdo-max-launches-molded-levo-max-threads/2473472/PDO MAX is introducing Molded Levo Max, bi-directional and barbed threads that are engineered for contouring the lower face, jawline, and general submentum area. PDO Max's Molded Levo Max threads grab submental fat and reposition it along the natural contours created
- Meet the Beauty Health Company’s New CFO: Michael Monahanhttps://modernaesthetics.com/news/meet-the-beauty-health-companys-new-ceo-michael-monahan/2473471/Michael Monahan is The Beauty Health Company’s new Chief Financial Officer, effective August 10, 2023. He succeeds Liyuan Woo, who is leaving BeautyHealth but will remain as an advisor until September 1, 2023 to assist with the transition. "Michael
- Evolus Unveils New Branding for Jeuveauhttps://modernaesthetics.com/news/evolus-unveils-new-branding-for-jeuveau/2473470/Evolus, Inc. is unveiling its new branding for Jeuveau (prabotulinumtoxinA-xvfs). The new Jeuveau imagery reflects today’s consumers, many of whom are millennials and younger. The “Jeuveau, You See Me” marketing campaign uses inclusive messaging to encourage
- L'Oréal CEO to Deliver Keynote at CES 2024https://modernaesthetics.com/news/loreal-ceo-to-deliver-keynote-at-ces-2024/2473457/L'Oréal CEO Nicolas Hieronimus will deliver the first-ever keynote from a beauty company at CES 2024. L'Oréal's keynote will showcase the role that sustainable, accessible and inclusive beauty tech plays in driving positive impact at an individu
- Venus Concept Introduces Medical Advisory Board for AI.MEhttps://modernaesthetics.com/news/venus-concept-introduces-medical-advisory-board-for-aime/2473449/The primary mission of the medical advisory board will be to provide strategic input, guidance, and clinical recommendations regarding the Company's emerging robotic technology, AI.ME, which received its first 510(k) clearance from the U.S. Food and Drug Administration (FDA) in December 2022,
- Acclaro Medical Rolls Our Rebranded UltraClear Cold Fiber Laserhttps://modernaesthetics.com/news/acclaro-medical-rolls-our-rebranded-ultraclear-cold-fiber-laser/2473448/Meet the newly re-branded UltraClear Cold Fiber Laser from Acclaro Medical. From a design perspective, rebranding encompasses an updated logo and color palette and aims to increase recognition of UltraClear's 3DIntelliPulse technology and its ability to provide optima
- What is Exosome Therapy? All Your Questions Answeredhttps://modernaesthetics.com/news/what-is-exosome-therapy-all-your-questions-answered/2473445/Exosomes are among today’s buzziest skincare ingredients, but what exactly are exosomes, how can you choose the best product to recommend to patients, and how can exosomes be used to complement in-office skin rejuvenation procedures? New York City dermatologist Marina I. Pere
- It's Camp Time for Dermatologistshttps://modernaesthetics.com/news/its-camp-time-for-dermatologists/2473432/As kids across the country got ready for summer camp, dermatologists flocked to Brooklyn, NY, for their own version of summer camp: Neutrogena’s immersive SkinU Summer Camp. Instead of learning to swim, sliding down a zipline, or playing tennis like kids in camp oft
- Botox Cosmetic Announces the Winners of the IFundWomen Grant Programhttps://modernaesthetics.com/news/botox-cosmetic-announces-the-winners-of-the-ifundwomen-grant-program/2473427/Twenty female entrepreneurs will receive funding and mentorship through Allergan’s BOTOX Cosmetic and IFundWomen grant program. "There were so many remarkable applications that featured thoughtful business solutions," says Carrie Strom, President, Global Aller
- Cutera Update: Agreements Made with Pura Vida and RTW; New Board Members Appointedhttps://modernaesthetics.com/news/cutera-update-agreements-with-pura-vida-and-rtw/2473414/Cutera announced that it has entered into cooperation agreements with two of its largest stockholders, Pura Vida Investments LLC and RTW Investments LP, which collectively own more than 15% of the company’s outstanding shares. Pursuant to the agreements, Cutera will appo